Outset Medical, Inc. (NASDAQ: OM) reported second-quarter 2026 revenue of $31.6 million, slightly ahead of the prior year and above analyst expectations of about $30.7 million. Gross profit rose to $13.3 million, reflecting stronger profitability at the top line even as the company remained unprofitable.
Operating loss widened to $15.7 million, while net loss attributable to common shareholders was $18.0 million, or $(0.97) per diluted share. Both figures were below the bottom line, with the loss per share coming in wider than the estimated $(0.74).
Cash used in operating activities improved sharply year over year to $(9.6 million), and capital spending stayed minimal at $111,000. Outset Medical ended the quarter with $35.0 million in cash and cash equivalents, while total liabilities fell to $48.1 million.
The stock fell 3.4% after the market close following the release.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Outset Medical, Inc. Insider Trading Activity
Outset Medical, Inc. insiders have traded $OM stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $OM stock by insiders over the last 6 months:
- RENEE GAETA (Chief Financial Officer) sold 17,672 shares for an estimated $87,299
- LESLIE TRIGG (Chair and CEO) has made 0 purchases and 2 sales selling 6,806 shares for an estimated $24,005.
- JOHN L. BROTTEM (General Counsel) has made 0 purchases and 2 sales selling 5,480 shares for an estimated $19,281.
- MARC NASH (EVP Operations R&D & Service) has made 0 purchases and 2 sales selling 3,399 shares for an estimated $11,940.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Outset Medical, Inc. Hedge Fund Activity
We have seen 53 institutional investors add shares of Outset Medical, Inc. stock to their portfolio, and 49 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALYESKA INVESTMENT GROUP, L.P. removed 1,614,582 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $6,199,994
- BML CAPITAL MANAGEMENT, LLC added 1,359,021 shares (+250.2%) to their portfolio in Q1 2026, for an estimated $5,218,640
- WOODLINE PARTNERS LP removed 1,033,418 shares (-77.9%) from their portfolio in Q1 2026, for an estimated $3,968,325
- AQR CAPITAL MANAGEMENT LLC added 627,922 shares (+348.1%) to their portfolio in Q1 2026, for an estimated $2,411,220
- PEAPOD LANE CAPITAL LLC added 331,951 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,434,028
- STRATOS WEALTH PARTNERS, LTD. added 200,546 shares (+inf%) to their portfolio in Q1 2026, for an estimated $770,096
- UBS GROUP AG added 179,339 shares (+245.1%) to their portfolio in Q1 2026, for an estimated $688,661
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Outset Medical, Inc. Analyst Ratings
Wall Street analysts have issued reports on $OM in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 02/12/2026
To track analyst ratings and price targets for Outset Medical, Inc., check out Quiver Quantitative's $OM forecast page.
Outset Medical, Inc. Price Targets
Multiple analysts have issued price targets for $OM recently. We have seen 2 analysts offer price targets for $OM in the last 6 months, with a median target of $9.0.
Here are some recent targets:
- Eric Winmill from Scotiabank set a target price of $3.0 on 06/15/2026
- Marie Thibault from BTIG set a target price of $15.0 on 02/12/2026
